1. Clark, JW, Sanoff, HK. Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach, https://www.uptodate.com/contents/systemic-therapy-for-nonoperable-metastatic-colorectal-cancer-selecting-the-initial-therapeutic-approach/ (accessed 26 December 2020).
Google Scholar2. Prewett, MC, Hooper, AT, Bassi, R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994–1003.
Google Scholar | Medline | ISI3. Karapetis, CS, Khambata-Ford, S, Jonker, DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757–1765.
Google Scholar | Crossref | Medline | ISI4. Blick, SK, Scott, LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67: 2585–2607.
Google Scholar | Crossref | Medline | ISI5. Manthri, S, Bandaru, S, Chang, A, et al. Cetuximab-Associated crescentic diffuse proliferative glomerulonephritis. Case Rep Nephrol 2017; 2017: 7964015.
Google Scholar | Medline6. Ito, C, Fujii, H, Ogura, M, et al. Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer. J Oncol Pharm Pract 2013; 19: 265–268.
Google Scholar | SAGE Journals7. Sasaki, K, Anderson, E, Shankland, SJ, et al. Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor. Am J Kidney Dis 2013; 61: 988–991.
Google Scholar | Crossref | Medline8. Koizumi, M, Takahashi, M, Murata, M, et al. Thrombotic microangiopathy associated with cetuximab, an epidermal growth factor receptor inhibitor. Clin Nephrol 2017; 87: 51–54.
Google Scholar | Crossref | Medline9. Izzedine, H, Boostandoost, H, Mathian, A. Panitumumab-Induced immune complex glomerulonephritis. Am J Kidney Dis 2017; 69: 320–321.
Google Scholar | Crossref | Medline10. Nishi, S, Ubara, Y, Utsunomiya, Y, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol 2016; 20: 342–370.
Google Scholar | Crossref | Medline11. Wu, MY, Chen, CS, Yiang, GT, et al. The emerging role of pathogenesis of IgA nephropathy. J Clin Med 2018; 7: 225.
Google Scholar | Crossref12. Davison, AM . Renal diseases associated with malignancies. Nephrol Dial Transplant 2001; 16: 13–14.
Google Scholar | Crossref | Medline13. Beck, LH . Membranous nephropathy and malignancy. Semin Nephrol. 2010;30:635–644.
Google Scholar | Crossref | Medline14. Jhaveri, KD, Wanchoo, R, Sakhiya, V, et al. Adverse renal effects of novel molecular oncologic targeted therapies: a Narrative Review. Kidney Int Rep 2016; 2: 108–123.
Google Scholar | Crossref | Medline15. Choudhury, D, Ahmed, Z. Drug-induced nephrotoxicity. Med Clin North Am 1997; 81: 705–717.
Google Scholar | Crossref | Medline | ISI16. Ocvirk, J, Cencelj, S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol 2010; 24: 453–459.
Google Scholar | Crossref | Medline17. Cao, Y, Liao, C, Tan, A, et al. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy 2010; 56: 459–465.
Google Scholar | Crossref | Medline